Recent 8-K filings for NNVC
Highest-materiality recent filing
NanoViricides reports NV-CoV-2-R shows nearly 2x intact remdesivir in plasma vs standard in rat study
- Almost double intact remdesivir in plasma on day 1 of dosing with NV-CoV-2-R vs standard remdesivir.
- After fifth dose (day 7), circulating remdesivir 75% greater in NV-CoV-2-R group.
-
NanoViricides raises ~$3.8M in registered direct offering of common stock and warrants
Gross proceeds of ~$3.8M from sale of 2,516,339 shares (or pre-funded warrants) and warrants to purchase 2,516,339 shares at $1.75.
-
NanoViricides raises $2M in registered direct offering of shares and warrants
Offering of 1,333,334 shares (or pre-funded warrants) plus 1,333,334 warrants at $1.75, priced at $1.50 per share.
-
NanoViricides raises $6M in registered direct offering and private placement with warrants
Offered 3,571,429 shares (or pre-funded equivalents) at $1.68/share for gross proceeds of ~$6M.
-
NanoViricides issues $1.5M convertible note to TheraCour in lieu of milestone payment
Issued $1.5M convertible promissory note to TheraCour (related party) in lieu of $1.5M cash milestone payment under Licensing Agreement.
-
Almost double intact remdesivir in plasma on day 1 of dosing with NV-CoV-2-R vs standard remdesivir.
-
NanoViricides licenses coronavirus drug field from TheraCour; no upfront cash
Exclusive worldwide license for coronavirus antiviral drugs; no upfront cash payment to TheraCour.
Materiality & sentiment trend
Max materiality 0.75 · Median 0.50 · Most common event other_material